Browse our anti-PLA2G16 (PLA2G16) Antibodies

Human HRAS-Like Suppressor 3 (PLA2G16) interaction partners

1. study uncovers two competing processes triggered by Picornaviridae virus entry: activation of a pore-activated clearance pathway and recruitment of a PLA2G16 phospholipase to enable genome release

2. Demonstrate increased PLA2G16 expression activates the MAPK (show MAPK1 Antibodies) pathway to enhance osteosarcoma metastasis.

3. our results revealed that H-rev107 (show HRASLS Antibodies) is also involved in lipid accumulation in liver cells through the POR (show POR Antibodies) pathway via its PLA2 (show YWHAZ Antibodies) activity.

4. Results show that osteosarcoma patients with metastasis showed higher expression of PLA2G16 at both the mRNA and protein levels and shorter overall survival suggesting it as significant prognostic factor for poor outcome.

5. the flexible main loop of H-REV107, but not that of TIG3, is critical for its NTD to modulate its CTD in inducing cell death.

6. crystal structure of the HRASLS3-LRAT (show LRAT Antibodies) chimeric enzyme in a thioester catalytic intermediate state revealed a major structural rearrangement accompanied by three-dimensional domain swapping dimerization not observed in native HRASLS (show HRASLS Antibodies)

7. several mutant p53 (show TP53 Antibodies) proteins bind the Pla2g16 promoter at E26 transformation-specific (ETS (show ETS1 Antibodies)) binding motifs and knockdown of ETS2 (show ETS2 Antibodies) suppressed mutant p53 (show TP53 Antibodies) induction of Pla2g16.

8. Our study further suggests that the PLA/AT activity of H-rev107 may play an important role in H-rev107-mediated RAS suppression.

9. an alternate mechanism for AdPLA in promoting adipose tissue lipolysis that is not contingent on the release of arachidonic acid and that is compatible with its combined PLA(1 (show POU2F3 Antibodies))/A(2) activity

10. Data show that acyl-modified forms of HRAS (show HRAS Antibodies)-like tumor suppressors HRASLS2 (show HRASLS2 Antibodies) and HRASLS3 mimicking lipolytic activity of lecithin retinol acyltransferase LRAT (show LRAT Antibodies).

Mouse (Murine) HRAS-Like Suppressor 3 (PLA2G16) interaction partners

1. several mutant p53 (show TP53 Antibodies) proteins bind the Pla2g16 promoter at E26 transformation-specific (ETS (show ETS1 Antibodies)) binding motifs and knockdown of ETS2 (show ETS2 Antibodies) suppressed mutant p53 (show TP53 Antibodies) induction of Pla2g16.

2. H-rev107 (show HRASLS Antibodies), through PTGDS (show PTGDS Antibodies), suppressed cell migration and invasion. Data suggest that the PGD2 (show PTGDS Antibodies)-cAMP-SOX9 (show SOX9 Antibodies) signal pathway might play an important role in H-rev107 (show HRASLS Antibodies)-mediated cancer cell invasion in testes.

3. H-rev107 (show HRASLS Antibodies) interferes with the biosynthesis of ether-type lipids and is responsible for the dysfunction of peroxisomes in H-rev107 (show HRASLS Antibodies)-expressing cells.

4. identification of an Sp1 (show SP1 Antibodies)/Sp3 (show SP3 Antibodies)-binding GC-box required for the transcription of H-rev107 (H-rev107 (show HRASLS Antibodies))

5. study found that AdPLA that was previously known as H-Rev-107 (show HRASLS Antibodies)/HRASLS3 is an adipose-specific, calcium-dependent histidine PLA2 (show PLA2G2A Antibodies)

6. HRASLS3 as one of the downstream effectors of PPARgamma (show PPARG Antibodies) action in adipogenesis.

Cow (Bovine) HRAS-Like Suppressor 3 (PLA2G16) interaction partners

1. Single nucleotide polymorphisms in the adipose specific phospholipase A2 are associated with growth traits in cattle.